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Background: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension
(PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The objective of this study was to evalu-
ate the change of right heart size and function assessed by echocardiography during long-term treatment with
riociguat.
Methods: We assessed patients who started riociguat treatment (1.0–2.5 mg tid) within the trials PATENT,
PATENTplus, EAS and CHEST and continued for 3–12 months. Echocardiography, 6-minute walking distance
(6MWD) and further clinical parameters were analyzed at baseline, after 3, 6 and 12 months. Right heart cathe-
terization was performed at baseline and after 3 months. For missing data we performed the last and baseline
observation carried forward (LOCF, BOCF) method as sensitivity analyses.
Results: Thirty-nine patients (21 PAH, 18 CTEPH, mean pulmonary arterial pressure 43 ± 2 mm Hg, PVR 600 ±
43 dyn∗s∗cm−5, 56.4% treatment-naïve)were included.Mean right ventricular (RV) area signiﬁcantly decreased
after 3 (−2.1± 3.9 cm2, equals−7.4± 15.3%, p= 0.002), 6 (−4.2± 3.2 cm2, equals−16.1± 11.5%, p b 0.001)
and 12 months (−5.9 ± 4.6 cm2, equals−22.1 ± 14.2%, p b 0.001) compared to baseline. Right atrial area sig-
niﬁcantly decreased after 12months (−3.5± 4.1 cm2, equals−16.8± 19.2%, p b 0.001) and TAPSE signiﬁcantly
improved after 6 (+2 ± 4.7, equals 12 ± 25.8%, p = 0.025) and 12 months (+3.6 ± 5.4, equals 21.0 ± 29.6%,
p = 0.002). Furthermore, RV wall thickness and 6MWD signiﬁcantly improved after 3, 6 and 12 months
(p b 0.05). Invasive hemodynamics signiﬁcantly improved after 3 months. Both LOCF and BOCF showed similar
signiﬁcance and lower effect sizes.
Conclusion: Long-term treatment with riociguat signiﬁcantly reduced right heart size and improved RV function
in PAH and CTEPH. Further prospective studies are needed to conﬁrm these results.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ability and freedom from bias of
Hypertension, Thoraxclinic at
g, Germany.
g.de (E. Grünig).
d Ltd. This is an open access article un1. Introduction
Pulmonary arterial hypertension (PAH) and chronic thromboembol-
ic pulmonary hypertension (CTEPH) are both rare diseases which are
usually diagnosed in late stages with functional class (FC) III or IV [1]
and lead to severe right heart failure with premature death [2,3]. Most
patients show a severely enlarged right heart with increased right ven-
tricular (RV) and right atrial (RA) areas (N16 cm2) and impaired cardiac
output (CO) at diagnosis. Riociguat is the ﬁrst drug that has beender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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week PATENT-1 study (Pulmonary Arterial Hypertension Soluble
Guanylate Cyclase-Stimulator Trial), riociguat signiﬁcantly improved
the primary endpoint 6-minute walking distance (6MWD) in patients
with PAH and several secondary endpoints, including pulmonary vascu-
lar resistance (PVR), N-terminal prohormone brain natriuretic peptide
(NT-proBNP), WHO-FC, time to clinical worsening and Borg dyspnea
score [4]. Patients completing PATENT-1 were eligible to enter the
PATENT-2 open-label extension study, which assessed the long-term
safety and efﬁcacy of riociguat in patients with PAH [4]. In the CHEST-
1 study (Chronic Thromboembolic Pulmonary Hypertension Soluble
Guanylate Cyclase-Stimulator Trial), riociguat signiﬁcantly improved
6MWD and a range of secondary endpoints, including PVR, NT-
proBNP, and WHO-FC in patients with inoperable CTEPH or persistent/
recurrent pulmonary hypertension (PH) after pulmonary endarterecto-
my [5]. In the EAS (Early Access Study) and PatentPlus [6] studies,
riociguat has also been used but without a placebo controlled arm.
Despite the great clinical relevance of the results provided by
riociguat studies [4,5], there is still a lack of data about the effects of
this drug on right heart size and performance (pump function), al-
though these parameters are independent prognostic markers [7].
These parameters are of importance taking into account that right
heart function is the key determinant of outcomes in PAH and CTEPH
patients [7,8]. RA area has been shown to be one of the most important
independent prognostic factors in PAH patients [9–11]. The area of the
right atrium is easy to measure non-invasively by echocardiography
and reﬂects RV pump function [12–14]. RV size is also a useful parame-
ter of utmost clinical importance since it reﬂects pressure and volume
load of the pulmonary circulation and is strongly associated with prog-
nosis of PH-patients [10,13]. Interestingly, in both PATENT-1 [4] and
CHEST-1 [5] studies, a remarkable improvement in CO was recorded
in patients receiving riociguat. However, in these studies cardiac
pump function was only an exploratory parameter. Therefore, in this
study we aimed to analyze, if the treatment with riociguat affects right
heart size and function after 3, 6 and 12 months.
2. Methods
2.1. Study population and design
For analysis we used the echocardiographic and clinical data obtain-
ed in themulticenter, parallel-group, placebo-controlled clinical studies
PATENT 1 and CHEST 1 and the corresponding long-term extension tri-
als and included the patients of the PATENTplus and EAS-trails. We
assessed all patients who received riociguat within these trails in the
PH-center of Heidelberg according to the following inclusion criteria:
1) enrollment in the riociguat trials (PATENT, PATENTplus, EAS and
CHEST); 2) PAH (for patients enrolled in PATENT, PATENTplus) or
CTEPH (for patients enrolled in CHEST and EAS) diagnosed according
to current guidelines [15]; 3) at least 12 weeks of riociguat administra-
tion and 4) since echocardiography was not mandatory in these trials a
further inclusion criterion for this analysis was that patients had re-
ceived at least 2 echocardiographic assessments with one at baseline
and a second after 3, 6 or 12 months.
Exceptminor changes in diuretics and anticoagulation dosages, con-
comitant medication remained stable throughout the observation peri-
od. An intra-individual comparison of patients who received riociguat
verum therapy either in the core and/or extension studies measured
at baseline, 3, 6 and 12 months by echocardiography was performed.
“Baseline” was considered as the time when patients started riociguat
therapy.
The primary end-point of the study was the change of RA and RV
areas from baseline to 12 months of riociguat therapy. Secondary end-
points were changes of RA and RV areas from baseline to 3 and
6 months, and changes after 3, 6 and 12 months in Tricuspid Annular
Plane Systolic Excursion (TAPSE), S′ wave of RV free wall pulsed tissueDoppler imaging (TDI), inferior vena cava (IVC) diameter and IVC col-
lapse, eccentricity index, S′ wave of RV free wall pulsed TDI, 6MWD,
and NT-proBNP serum levels. Further secondary end-point was the
change of hemodynamic parameters assessed by right heart catheteri-
zation (RHC) at baseline and after 3 months. All patients gave written
informed consent to the riociguat trials, which were approved by the
Ethics Committee at theMedical Faculty of the University of Heidelberg.
2.2. Clinical assessment
Clinical parameters at each time-point included WHO-FC, 6MWD
and Borg dyspnea score. 6MWD was carried out under standardized
conditions [16]. At the end of the 6-minute walking test, the Borg dys-
pnea scale (with 6 representing no exertion and 20 maximal exertion)
was assessed [17]. Furthermore, safety and tolerability were assessed
by monitoring of adverse reactions. Change of PH-speciﬁc treatment
was recorded throughout the study. Routine laboratory parameters as
hemoglobin and creatinine have been obtained at baseline, 3, 6, and
12 months.
2.3. Echocardiographic assessment
Two-dimensional and color-ﬂowguided continuous-wave-Doppler-
echocardiographic recordingswere routinely obtained at rest by experi-
enced cardiac sonographers (EG and CN) using 2.5 MHz Duplex probes
and conventional equipment (Vivid 7, GE Healthcare, Milwaukee,
Wisconsin) every three months in our center. In accordance with the
American Society of Echocardiography (ASE) guidelines [18], RA area
and RV area were measured at the end of ventricular diastole (largest
volume), tracing following the endocardium from the lateral aspect of
the tricuspid annulus to the septal aspect, excluding the area of the an-
nulus and the leaﬂets (with regard to RA area) and excluding the area of
the annulus and trabecular structures (with regard to RV area). S wave
of the RV free wall wasmeasured using TDI. TAPSEwas calculated using
M-mode from the lateral tricuspid annulus.
2.4. Hemodynamics
RHC was performed at baseline and after 3 months in the PATENT,
CHEST and PATENTplus core studies. The examination was performed
in a supine position using the transjugular approach with an 8F
introducer set (MXI100, MEDEX, Smiths Group PLC, UK). RHC was
done by triple-lumen 7F-Swan–Ganz thermodilution catheters (Ed-
wards Lifesciences, Irvine, CA, USA). CO was measured at least in tripli-
cate by thermodilution with a variation of less than 10% between the
measured values. The zero reference point for pressure recordings was
set at the level of the right atrium in the midaxillary line (phlebostatic
axis). All examinations and measurements were performed by the
same experienced team.
2.5. Statistical analysis
The analysis was performed by two statisticians (NE and CF). Data
are given as mean ± standard deviation for each time point. We also
present themeanof individual changes as absolute values and as percent-
age. The comparisons of baseline and 3, 6 and 12 months for echocardio-
graphic parameters, 6MWD, Borg dyspnea index, RHC parameters,
biochemical assay blood pressure and heart rate were conducted by
paired t-tests, and the McNemar test for WHO-FC. All tests were two-
sided and a p-value of 0.05 was considered statistically signiﬁcant. Efﬁca-
cy parameters were available for statistical analysis at baseline and after
3 months in all patients. We performed a nonparametric sensitivity anal-
ysis by using theWilcoxon rank-sum test. To deal with missing data, two
imputationmethods: the last observation carried forward (LOCF) and the
baseline observation carried forward (BOCF) methods were performed.
This means, that in case of a missing value, the value from the previous
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is imputed.
3. Results
3.1. Study population
Thirty-nine patients were enrolled in the selected riociguat studies
at the PH center in Heidelberg. Baseline characteristics of the patients
are shown in Table 1. More than half of the patients were treatment
naïve (56.4%) and most of the patients (87%) have been up titrated to
the maximum riociguat dosage of 2.5 mg, three times a day. Five pa-
tients were also treated with PDE5 inhibitors, which were allowed in
the PATENTplus trial only. All 39 patients completed 3 months of
riociguat therapy, 6- and 12-month follow-up was completed by 32
and 27 patients, respectively (see Fig. 1).
Two patients withdrew therapy with riociguat before the 12 month
follow-up: after 4 months of treatment one patient experienced diar-
rhea reversible after riociguat withdrawal, one patient who also re-
ceived treatment with an endothelin receptor antagonist, which is
associated with liver toxicity [19], showed a sudden rise of hepatic
transaminases. In this patient, both treatments were withdrawn and
switched to other PAH-drugs for safety reasons.
Another ﬁve patients did not complete 6months and additional four
patients (in total 9) did not complete 12 months of riociguat treatment
at the end of the analysis. Moreover, one patient was lost to follow-up
after 6 months of therapy. After three months, one patient received ad-
ditional PH-targeted medication with inhaled Iloprost and Bosentan.
This patient had been on placebo during the PATENT-1 study.
3.2. Change of the right heart size
After 3 months of therapy, mean RV area signiﬁcantly reduced by
2.1 ± 3.9 cm2 (p = 0.002, equals −7.4 ± 25.3%) and continued toTable 1
Baseline characteristics of the study population.
Patients 39
Female sex (%) 23 (58.7%)
Age years 55.72 ± 15.11
BSA (m2) 1.95 ± 0.32
WHO functional class n (%)
II 11 (28.2%)
III 28 (71.8%)
Cause of PH (%)
IPAH 10 (25.6%)
Connective tissue diseases—APAH 10 (25.6%)
Portal hypertension—APAH 1 (2.6%)
Inoperable—CTEPH 5 (12.5%)
Persistent/recurrent—CTEPH 13 (33.3%)
PH-targeted medication (%)
ERA 12 (30.8%)
PDE5-inhibitor 2 (5.1%)
ERA + PDE5-inhibitor 3 (7.7%)
Treatment naïve 22 (56.4%)
Riociguat ﬁnal dose (mg TID) 2.3 ± 0.5
Baseline 6MWD 378.24 ± 100.3
Right heart catheterization
Mean pulmonary artery pressure (mm Hg) 43.18 ± 13.29
PVR (dyn∗s∗cm−5) 600.08 ± 267.95
RA pressure (mm Hg) 8.11 ± 5.7
PAWP (mm Hg) 9.42 ± 3.41
Cardiac output (L∗min−1) 4.8 ± 1.0
Cardiac index (L∗min−1∗m−2) 2.59 ± 0.47
Data are presented as n, n (%) or mean ± SD. WHO:World Health Organization; BSA: body
surface area; PH: pulmonary hypertension; IPAH: idiopathic pulmonary arterial hyperten-
sion; APAH: associated pulmonary arterial hypertension; CTEPH: chronic thromboembolic
pulmonary hypertension; ERA: endothelin receptor antagonists; PDE5: phosphodiesterase-
5; TID: three times a day; 6MWD: six-minutewalking distance; PVR: pulmonary vascular re-
sistance; PAWP: pulmonary arterial wedge pressure.decrease after 6 months by 4.2 ± 3.2 cm2 (p b 0.001, equals−16.1 ±
11.5%) as well as after 12 months by 5.9 ± 4.6 cm2 (p b 0.001, equals
−22.1 ± 14.2%), respectively. Similarly, RA area continuously de-
creased during the study course by 1.1 ± 4.0 cm2 (p = 0.11, equals
−4.4 ± 19.4%), 1.5 ± 4.2 cm2 (p = 0.06, equals −6.8 ± 22.6%) and
3.5 ± 4.1 cm2 (p b 0.001, equals −16.8 ± 19.2%) after 3, 6 and
12 months compared to baseline, respectively. Individual RA areas at
baseline and after 12 months are given in Fig. 2.
Riociguat administration was also associated with a signiﬁcant re-
duction of RV free wall thickness by 1.1 ± 2.8 mm (p b 0.05, equals
−6.5 ± 20.4%), 1.4 ± 3.3 mm (p b 0.01, equals 9.8 ± 27.3%) and
1.9 ± 3.5 mm (p b 0.01, equals 3.8 ± 26.8%) after 3, 6 and 12 months
respectively. Both the LOCF and BOCF showed identical signiﬁcance
and lower effect sizes (see Figs. 3 and 4).3.3. Change of the right heart function
Improvement during the study was also seen in further parameters
reﬂecting right heart function. Compared to baseline values, TAPSE sig-
niﬁcantly improved after 6 (+2 ± 4.7 mm, p = 0.025, equals 12.1 ±
25.8%) and 12 months (3.6 ± 5.4 mm, p = 0.002, equals 21.0 ±
29.6%; Fig. 5). The signiﬁcant improvement of the right heart function
was also reﬂected in the velocity of the annular movement, measured
by TDI Swave. Tricuspid annular velocity showed a signiﬁcant improve-
ment after 12 months with an increase of 1.7 ± 2.9 mm/s (p = 0.006,
equals 19 ± 32%) while the improvement after 3 and 6 months was
not statistically signiﬁcant (p= 0.062, p = 0.089, Table 2). Accordingly
with the reduction of RV sizewe observed a signiﬁcant improvement of
RV remodeling assessed by LV eccentricity index after 6 months
(−0.3 ± 0.5, p = 0.003, equals −1.9 ± 17.3%) and 12 months
(−0.1 ± 0.2, p = 0.03, equals −6.7 ± 16.0%). PA and IVC diameters
did not signiﬁcantly change during the study course. Nonparametric
sensitivity analysis showed similar signiﬁcant changes. Both LOCF and
BOCF conﬁrmed the signiﬁcant results observed in the complete case
analysis (see Fig. 4).
RHCwas performed at baseline and after 3 months in the PATENT-1
and CHEST-1 trials (Table 2). Thus, only hemodynamic data of patients
who received verum therapy in the core studies were analyzed.
Riociguat administration was associated with a signiﬁcant reduction in
systolic (sPAP) and mean pulmonary arterial pressure (mPAP) by
6.2 ± 12.5 mm Hg and 6.9 ± 11.9 mm Hg, respectively (p = 0.03
each). No changes in diastolic pulmonary arterial pressure (dPAP)
were recorded. A remarkable improvement of CO (+1.7 ± 1.0 L/min,
p b 0.001) and cardiac index (+0.9 ± 0.5 L/min/m2, p b 0.001) was re-
corded. Accordingly, PVR substantially improved after 3 months
(−207 ± 151 dyn∗s∗cm−5 compared to baseline, p b 0.001). RA pres-
sure (indicating central venous pressures) and pulmonary arterial
wedge pressure (PAWP) did not change after 3 months.3.4. Change of further clinical parameters
Physical exercise capacity, measured by 6MWD, showed a signiﬁ-
cant improvement after 3 and 6 months (3 months +27 ± 60 m,
p = 0.008, 6 months +51 ± 71 m compared to baseline, p = 0.001)
and a further albeit not statistically signiﬁcant improvement after
12 months (+33± 90m, p= 0.083, equals 11.2± 33.6%). The smaller
improvement after 12 months was mainly caused by one patient
who decreased in her walking distance by almost 180 m (~50%),
which was due to acute pain by her knee- and hip-arthrosis. Leaving
this patient out of the analysis, thewalking distance after 12months im-
proved signiﬁcantly (p = 0.01). Borg dyspnea index, blood gas ex-
change (measured as oxygen saturation at rest and at the end of
6minutewalking test) andWHO-FC, did not signiﬁcantly change during
the study course.
Fig. 1. Flow-chart of study population. Number of patients included in the analysis, exclusions and loss to follow-up are given for each time point.
22 A.M. Marra et al. / International Journal of Cardiology 195 (2015) 19–263.5. Renal function, hemoglobin and NT-proBNP serum values
An unexpected improvement in renal function (although always
within the normal ranges) was recorded after 6 months (15% decrease
in serum creatinine values after 6 months p b 0.05) with stabilization
after 12 months (p b 0.001 vs baseline). Even thoughwe observed a re-
markable reduction in serum NT-proBNP levels, the statistical signiﬁ-
cance was not reached. No changes were recorded with regard to
hemoglobin concentration.3.6. Outcomes and tolerability
In one patient, PH-speciﬁc treatment was escalated after 4 months.
Two further patients received an endothelin receptor antagonist after
3 and 6 months respectively. As these two patients did not complete
further follow-up assessments, data after initiation of further PH-
treatment was not included in the analysis.
As reported above, 2 patients experienced side effects within the ﬁrst
3months of the study,which led towithdrawal of riociguat. In one patientFig. 2. Individual RAarea at baseline and after 1 year. RA areas for eachpatient are given for
baseline and 12months, circles for females and triangles formales. The corresponding cut-
off values with 15 cm2 for females (dashed) and 16 cm2 for males (straight) are given as
horizontal and vertical lines. The diagonal represents no change between time points.who experienced diarrhea, the side effect stopped after withdrawal of
riociguat, suggesting probable relation to drug administration.
In a second patient, a sudden rise of transaminase was recorded (3
times the upper limit of normal). In this patient, riociguat was with-
drawn for safety reasons. However, the patient was already taking
Ambrisentan, which is infrequently associated with liver toxicity [19].
No deaths, unplanned hospital admissions, lung transplantations and
sudden worsening of functional status were recorded during the study
course. All RHCs have been performed without complications.
4. Discussion
This is the ﬁrst study demonstrating that riociguat administration
signiﬁcantly improved or even normalized mean RA and RV areas
after 12 months of treatment in patients with severe PAH and CTEPH
who hadmarkedly enlargedmean right heart size at baseline. Riociguat
treatment also improved RV pump function and reduced hypertrophy
after 3 months measured by RCH and echocardiography. The improve-
ment of right heart size and function was associated with an improve-
ment of exercise capacity, WHO-FC and renal function. Hemodynamic
changes measured by RHC showed a signiﬁcant increase of cardiac
index with signiﬁcant decrease of PVR.
4.1. Effect of riociguat on right heart size and function
The observed changes of clinical parameters are in-linewith the pre-
vious results of riociguat trials. According to previously published stud-
ies [4,5] riociguat administration was associated with an improvement
of hemodynamics assessed by RHC. Speciﬁcally a decrease in sPAP,
mPAP and PVR and a remarkable improvement of CO and cardiac
index were recorded [4,5]. Both PATENT and CHEST reported a signiﬁ-
cant improvement in 6MWD (primary end-point of the study) and
hemodynamics (secondary end-point) associated with riociguat ad-
ministration. However, in the last years 6MWD [20,21] and hemody-
namics [22] as surrogate end-points of clinical events have been
questioned. A growing body of evidences suggests that RV failure is a
key prognostic determinant in both clinical conditions PAH and CTEPH
[23,24]. Echocardiography is a valuable tool for assessing right heart
size and function and in turn to assess prognosis of PAH and CTEPH
patients [7]. Both TAPSE [25] aswell as RV andRA areas [10] are strongly
associated with prognosis in PAH patients. Furthermore, RA area
at baseline seems to be one of the most robust echocardiographic
Fig. 3.Mean RV area during the course of the study. For each time point mean RV area± standard error of themean is given. p-Values are given compared to baseline for all analyses. The
complete case analysis is given as straight line, the last observation carried forward as dashed line and baseline observation carried forward as dotted line. Mean RV area signiﬁcantly de-
creased at all time-points compared to baseline. Results of the two imputation methods showed the same signiﬁcances with smaller effect sizes.
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ﬂect an improved RV contractile reserve andmay be of high clinical rel-
evance. Altogether, 22 of 26 patients who performed their 12 months
assessment showed an improvement of RA area. Using the proposed
cut-off for a normal RA area of 15 cm2 in female and 16 cm2 in males
[14] seven patients who presented with baseline values above these
cut-offs showed values within the normal ranges after one year of
riociguat treatment. For the RV area, the cut-off value suggested byFig. 4.Mean RA area during the course of the study. For each time point mean RV area± standa
complete case analysis is given as straight line, the last observation carried forward as dashed li
creased after 12 months compared to baseline. Results of the two imputation methods showedrecent echocardiographic guidelines [18] is 25 cm2 for male and female.
Regarding this cut-off, eight patients who presented with baseline
values above 25 cm2 showed values below this cut-off after 12 months.
However, the role of these echocardiographic parameters as a
follow-up marker to guide therapy needs to be further assessed [26].
This is due to two main reasons. First, the lack of standardized echocar-
diographic methods of assessing right heart size and function of the RV
togetherwith technical difﬁculties in obtaining reproducible right-sidedrd error of themean is given. p-Values are given compared to baseline for all analyses. The
ne and baseline observation carried forward as dotted line. Mean RA area signiﬁcantly de-
the same signiﬁcances with smaller effect sizes.
Fig. 5.Mean TAPSE during the course of the study. For each time point mean RV area ± standard error of themean is given. p-Values are given compared to baseline for all analyses. The
complete case analysis is given as straight line, the last observation carried forward as dashed line and baseline observation carried forward as dotted line. Mean TAPSE signiﬁcantly de-
creased after 6 and 12 months compared to baseline.
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ing the effect of a PAH-targeted drug on right heart size and function.
In a recent trial [27] the acute hemodynamic effect of a single dose of
riociguat was tested in patients affected by left heart failure with pre-
served ejection fraction (HFpEF). In this study 2mg of riociguat reduced
RV area by−5.6 cm2. The cardioprotective effect due to riociguat ad-
ministration might lead to a future use of this treatment in heart failure
patients [6]. However this ﬁnding should be conﬁrmed by futureTable 2
Echocardiographic assessment, 6MWD, WHO class, right heart catheterization at baseline and
Baseline 3 mo
Echocardiographic parameters, n 39 39
RA area, cm2 19.49 ± 5,79 18.4
RV area, cm2 24.87 ± 6.84 22.8
TAPSE, mm 19.56 ± 3.99 20.1
S′ wave lateral wall TDI, mm 10.90 ± 2.68 11.6
RV free wall thickness, mm 9.50 ± 3.87 8,34
IVC diameter, mm 17.12 ± 4.70 17.5
PA diameter, mm 24.24 ± 3.32 24.8
LV eccentricity index 1.21 ± 0.25 1.20
6MWD, m 378.24 ± 100.30 407.
Borg dyspnea index 4.41 ± 1.83 4.28
Oxygen saturation at rest 98.18 ± 2.42 95.6
Oxygen saturation during exercise 89.64 ± 5.80 90.2
WHO functional class 2.72 ± 0.46 2.74
Right heart catheterization, n 39 22
sPAP, mm Hg 75.13 ± 22.11 68.1
mPAP, mm Hg 43.18 ± 13.29 36.2
dPAP, mm Hg 26.90 ± 10.21 23.7
PVR, dyn∗s∗cm−5 600.08 ± 267.95 370.
RA pressure, mm Hg 8.11 ± 5.70 7.45
PAWP, mm Hg 9.42 ± 3.41 10.1
Cardiac output, L∗min−1 4.80 ± 1.0 6.69
Cardiac index, L∗min−1∗m−2 2.59 ± 0.47 3.57
Creatinine, mg/dl 0.97 ± 0.32 0.95
Hemoglobin, mg/dl 14.10 ± 1.90 13.9
NT-proBNP, pg/dl 1722.26 ± 2891.30 1486
Data are presented as n, n (%) or mean± SD. RA: right atrium, RV: right ventricle; TAPSE: Tricus
6MWD: 6-minute walking distance; SvO2%: partial venous oxygen saturation; SaO2%: partial ar
sure; PVR: pulmonary vascular resistance; PAWP: pulmonary arterial wedge pressure.*: p b 0.05
to baseline.research. One patient received additional medication 4 months after
baseline, which might have inﬂuenced the results. However, results
were similar when leaving this patient out of the analysis.
4.2. Molecular and cellular effects of riociguat on the right ventricle
The sGC/NO pathway plays a pivotal role in PAH and represents one
of the main therapeutic targets of PAH speciﬁc drugs [28]. The directafter 3, 6 and 12 months of riociguat administration.
nths 6 months 12 months
32 27
4 ± 6.41 17.58 ± 6.42 15.27 ± 5.02***
2 ± 6.47** 20.94 ± 6.08*** 19.50 ± 5.78***
8 ± 4.42 21.48 ± 5.28* 22.92 ± 5.72**
4 ± 3.00 12.00 ± 3.41 12.96 ± 3.35**
± 2.78* 8.28 ± 3.39** 8.12 ± 2.95**
9 ± 5.57 16.83 ± 4.48 15.62 ± 3.85
0 ± 3.06 22.19 ± 6.28 23.38 ± 2.86
± 0.28 0.95 ± 0.58** 1.09 ± 0.17*
31 ± 110.51** 440.60 ± 104.95*** 408.54 ± 130.02**
± 1.82 3.97 ± 1.92 4.04 ± 1.68
8 ± 2.01 95.51 ± 2.46 95.61 ± 2.46
3 ± 5.10 90.92 ± 4.39 90.96 ± 5.13
± 0.44 2.75 ± 44 2.69 ± 0.47
4 ± 18.36* – –
7 ± 12.54** – –
3 ± 9.96 – –
64 ± 187.86*** – –
± 5.06 – –
8 ± 3.13 – –
± 1.49*** – –
± 0.52*** – –
± 0.35 0.82 ± 0.36* 0.82 ± 0.27**
0 ± 2.16 14.00 ± 2.32 13.81 ± 2.04
.10 ± 2748.52 1240 ± 2885.92 497.58 ± 720.75
pid Annular Plane Systolic Excursion; TDI: tissue Doppler-imaging; IVC: inferior vena cava,
terial oxygen saturation;WHO:World Health Organization; PAP: pulmonary arterial Pres-
; **: p b 0.01; ***: p b 0.001. All p-values are based on two-tailed student's t-test compared
25A.M. Marra et al. / International Journal of Cardiology 195 (2015) 19–26pharmacological stimulation of sGC by riociguat demonstrated to re-
verse right heart dilatation and hypertrophy and to improve systolic
function in several preclinical studies that have employed different an-
imal models of PH [29–31]. Of note, riociguat demonstrated to exert a
cardio-protective action of higher extent compared to sildenaﬁl, as
demonstrated by Lang et al. who have tested both drugs in rat PAH
model exposed to vascular endothelial growth factor receptor antago-
nist SU5416 and hypoxia [29].
Riociguat might exert cardio-protective effects through different
mechanisms. A reduction of collagen content was found in the afore-
mentioned study performed by Lang et al. [29]. In a study of Geschka
S. et al. [32] riociguatwas administrated toDahl salt-sensitive ratsmain-
tained on a high salt diet for 14 weeks. Histological examination of the
heart revealed that riociguat carried a remarkable positive effect on ﬁ-
brotic tissue remodeling and degeneration. Furthermore, the authors
recorded that riociguat was able to reduce the mRNA expression in
the myocardium of pro-ﬁbrotic biomarkers such as osteopontin, tissue
inhibitor of matrix metalloproteinase-1 and plasminogen activator
inhibitor-1. In the same study riociguat was also able to reducemyocar-
dial inﬂammation, cardiomyocyte diameter and increase RV contractil-
ity [32].
However, the speciﬁc mechanism of action of riociguat on right
heart size and function remains to be investigated.
4.3. Limitations
This study presents some limitations. For our analysis of long-term
effects we did not have a placebo control group. However, in our
study cohort most patients showed an improvement in RA (26% went
into normal ranges after 1 year [14]) and RV areas (30.7%went into nor-
mal ranges after 1 year [18]). Another limitation is that our cohort is
only a small part of the entire study population enrolled in riociguat tri-
als [4,5]. Our sample almost mirrored the baseline characteristics of
these studies, except for the lack of WHO class IV patients, which in
turn represent only a small amount of the study population. At database
closure some patients did not yet attend their routine visits in our center
and could therefore not be included into the analysis of original data. All
patients were contacted via phone and showed no clinical worsening
or worsening of symptoms. The sample size did also not allow a
subanalysis regarding PH speciﬁc therapy. Future research should also
focus on whether treatment-naïve patients on riociguat monotherapy
show a larger improvement than patients who already receive PH
targeted therapy.
5. Conclusion
Long-term treatment with riociguat signiﬁcantly reduced and even
normalized right heart size and improved RV function in PAH and
CTEPH. Riociguat treatment also improved RV pump function and re-
duced hypertrophy after 3 months measured by RHC and echocardiog-
raphy. The improvement of right heart size and functionwas associated
with an improvement of exercise capacity, WHO-FC and renal function.
Further prospective studies are needed to conﬁrm these results.
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